AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

ARS Pharmaceuticals, Inc. Director's Dealing 2024

Jan 4, 2024

32159_dirs_2024-01-04_294ec32d-dc69-4dd4-b3ab-7c97d0b28ac2.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ARS Pharmaceuticals, Inc. (SPRY)
CIK: 0001671858
Period of Report: 2024-01-02

Reporting Person: Dorsey Brian (Chief Operating Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2024-01-02	Stock option (right to buy)	$5.58	A	350000	Acquired	2034-01-01	Common Stock (350000)	Direct

Footnotes

F1: 25% of the shares subject to the option shall vest on January 1, 2025, and the remaining shares will vest monthly thereafter over three years.